AstraZeneca Iressa (correction)
Executive Summary
AstraZeneca's non-small cell lung cancer agent Iressa (gefitinib) showed no improvement in survival as add-on therapy to standard chemotherapy in the Phase III INTACT trials. "The Pink Sheet" incorrectly described the regimen in the INTACT studies (1"The Pink Sheet" Sept. 16, p. 25). The Sept. 24 FDA Oncologic Drugs Advisory Committee review of Iressa is expected to proceed as scheduled...